Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.

Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C.

Front Immunol. 2019 Aug 14;10:1943. doi: 10.3389/fimmu.2019.01943. eCollection 2019.

2.

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, Lammerts van Bueren J, Chiu C, Doshi P, Pérez-Galán P.

Haematologica. 2019 Jul 11. pii: haematol.2018.211904. doi: 10.3324/haematol.2018.211904. [Epub ahead of print]

3.

Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.

Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, Franchini DM, Laurent C, Morin R, Lagarde JM, Ysebaert L, Ligat L, Jean C, Savina A, Klein C, Céspedes AM, Perez-Galan P, Fournié JJ, Bezombes C.

Oncoimmunology. 2018 Dec 17;8(3):1554175. doi: 10.1080/2162402X.2018.1554175. eCollection 2019.

PMID:
30723586
4.

Increasing Uptake of Silica Nanoparticles with Electroporation: From Cellular Characterization to Potential Applications.

Phonesouk E, Lechevallier S, Ferrand A, Rols MP, Bezombes C, Verelst M, Golzio M.

Materials (Basel). 2019 Jan 7;12(1). pii: E179. doi: 10.3390/ma12010179.

5.

Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.

Péricart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, Bezombes C, Laurent G, Brousset P, Fournié JJ, Laurent C.

Cancers (Basel). 2018 Oct 31;10(11). pii: E415. doi: 10.3390/cancers10110415.

6.

IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model.

Duault C, Betous D, Bezombes C, Roga S, Cayrol C, Girard JP, Fournié JJ, Poupot M.

Eur J Immunol. 2017 Dec;47(12):2137-2141. doi: 10.1002/eji.201747093. Epub 2017 Sep 29.

7.

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C.

Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Review.

8.

Radiolabelling rituximab with (99m)Tc in three steps procedure.

Fontan C, Bezombes C, Salabert AS, Costes J, Lopez R, Fournie JJ, Avet-Loiseau H, Coulais Y, Payoux P, Tafani M.

J Labelled Comp Radiopharm. 2015 Jun 15;58(7):274-80. doi: 10.1002/jlcr.3283. Epub 2015 May 27.

PMID:
26017396
9.

Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes.

Decaup E, Duault C, Bezombes C, Poupot M, Savina A, Olive D, Fournié JJ.

Immunol Lett. 2014 Sep;161(1):133-7. doi: 10.1016/j.imlet.2014.05.011. Epub 2014 Jun 9.

PMID:
24925024
10.

The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.

Kheirallah S, Fruchon S, Ysebaert L, Blanc A, Capilla F, Marrot A, Alsaati T, Frenois FX, Benhadji KA, Fournié JJ, Laurent G, Bezombes C.

Br J Pharmacol. 2013 Dec;170(7):1374-83. doi: 10.1111/bph.12351.

11.

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.

Decaup E, Jean C, Laurent C, Gravelle P, Fruchon S, Capilla F, Marrot A, Al Saati T, Frenois FX, Laurent G, Klein C, Varoqueaux N, Savina A, Fournié JJ, Bezombes C.

Blood Cancer J. 2013 Aug 9;3:e131. doi: 10.1038/bcj.2013.32.

12.

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Fournié JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G.

Cell Mol Immunol. 2013 Jan;10(1):35-41. doi: 10.1038/cmi.2012.39. Epub 2012 Dec 17. Review.

13.

Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis.

Fruchon S, Kheirallah S, Al Saati T, Ysebaert L, Laurent C, Leseux L, Fournié JJ, Laurent G, Bezombes C.

Leukemia. 2012 Apr;26(4):795-805. doi: 10.1038/leu.2011.248. Epub 2011 Sep 16.

PMID:
21926965
14.

Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives.

Bezombes C, Fournié JJ, Laurent G.

Mol Cancer Res. 2011 Nov;9(11):1435-42. doi: 10.1158/1541-7786.MCR-11-0154. Epub 2011 Sep 15. Review.

15.

Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.

Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, Bezombes C, Quillet-Mary A, Poupot M, Ysebaert L, Laurent G, Fournié JJ.

Curr Drug Targets. 2010 Jul;11(7):790-800. Review.

PMID:
20370648
16.

Rituximab inhibits B-cell receptor signaling.

Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fournié JJ, Laurent G, Bezombes C.

Blood. 2010 Feb 4;115(5):985-94. doi: 10.1182/blood-2009-08-237537. Epub 2009 Nov 17.

PMID:
19965664
17.

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.

Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournié JJ.

Blood. 2009 May 14;113(20):4875-84. doi: 10.1182/blood-2008-08-172296. Epub 2009 Mar 10.

PMID:
19278954
18.

PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma.

Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D, Bezombes C.

Blood. 2008 Jan 1;111(1):285-91. Epub 2007 Sep 12.

PMID:
17855629
19.

PKCzeta protects against UV-C-induced apoptosis by inhibiting acid sphingomyelinase-dependent ceramide production.

Charruyer A, Jean C, Colomba A, Jaffrézou JP, Quillet-Mary A, Laurent G, Bezombes C.

Biochem J. 2007 Jul 1;405(1):77-83.

20.

Syk-dependent mTOR activation in follicular lymphoma cells.

Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, Bezombes C.

Blood. 2006 Dec 15;108(13):4156-62. Epub 2006 Aug 15.

PMID:
16912221
21.

UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal.

Charruyer A, Grazide S, Bezombes C, Müller S, Laurent G, Jaffrézou JP.

J Biol Chem. 2005 May 13;280(19):19196-204. Epub 2005 Mar 11.

22.

Nerve growth factor-induced protein kinase C stimulation contributes to TrkA-dependent inhibition of p75 neurotrophin receptor sphingolipid signaling.

Plo I, Bono F, Bezombes C, Alam A, Bruno A, Laurent G.

J Neurosci Res. 2004 Aug 15;77(4):465-74.

PMID:
15264216
23.

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains.

Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Müller S, Jaffrézou JP, Laurent G.

Blood. 2004 Aug 15;104(4):1166-73. Epub 2004 May 4.

PMID:
15126316
24.

Implication of raft microdomains in drug induced apoptosis.

Bezombes C, Laurent G, Jaffrézou JP.

Curr Med Chem Anticancer Agents. 2003 Jul;3(4):263-70. Review.

PMID:
12769772
25.

Phosphatidylcholine-derived phosphatidic acid and diacylglycerol are involved in the signaling pathways activated by docetaxel.

Maestre N, Bezombes C, Plo I, Levade T, Lavelle F, Laurent G, Jaffrézou JP.

J Exp Ther Oncol. 2003 Jan-Feb;3(1):36-46.

PMID:
12724857
26.

Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation.

Bezombes C, de Thonel A, Apostolou A, Louat T, Jaffrézou JP, Laurent G, Quillet-Mary A.

Mol Pharmacol. 2002 Dec;62(6):1446-55.

PMID:
12435813
27.

Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin.

Mas VM, Hernandez H, Plo I, Bezombes C, Maestre N, Quillet-Mary A, Filomenko R, Demur C, Jaffrézou JP, Laurent G.

Blood. 2003 Feb 15;101(4):1543-50. Epub 2002 Oct 24.

PMID:
12406911
28.

Daunorubicin- and Ara-C-induced interphasic apoptosis of human type II leukemia cells is caspase-8-independent.

Terrisse AD, Bezombes C, Lerouge S, Laurent G, Jaffrézou JP.

Biochim Biophys Acta. 2002 Oct 10;1584(2-3):99-103.

PMID:
12385892
29.

Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts.

Grazide S, Maestre N, Veldman RJ, Bezombes C, Maddens S, Levade T, Laurent G, Jaffrézou JP.

FASEB J. 2002 Oct;16(12):1685-7. Epub 2002 Aug 21.

PMID:
12206990
30.

Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C.

Bezombes C, Plo I, Mansat-De Mas V, Quillet-Mary A, Nègre-Salvayre A, Laurent G, Jaffrézou JP.

FASEB J. 2001 Jul;15(9):1583-5. No abstract available.

PMID:
11427493
31.

Lysosomal sphingomyelinase is not solicited for apoptosis signaling.

Bezombes C, Ségui B, Cuvillier O, Bruno AP, Uro-Coste E, Gouazé V, Andrieu-Abadie N, Carpentier S, Laurent G, Salvayre R, Jaffrézou JP, Levade T.

FASEB J. 2001 Feb;15(2):297-9. Epub 2000 Dec 8.

PMID:
11156942
32.

Stress-induced apoptosis is not mediated by endolysosomal ceramide.

Ségui B, Bezombes C, Uro-Coste E, Medin JA, Andrieu-Abadie N, Augé N, Brouchet A, Laurent G, Salvayre R, Jaffrézou JP, Levade T.

FASEB J. 2000 Jan;14(1):36-47.

PMID:
10627278
33.

Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin.

Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaïeb A, D'orgeix AD, Laurent G, Jaffrézou JP.

Mol Pharmacol. 1999 Nov;56(5):867-74.

PMID:
10531389
34.

Positive feedback control of neutral sphingomyelinase activity by ceramide.

Jaffrézou JP, Maestre N, de Mas-Mansat V, Bezombes C, Levade T, Laurent G.

FASEB J. 1998 Aug;12(11):999-1006.

PMID:
9707172
35.

Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833.

Bezombes C, Maestre N, Laurent G, Levade T, Bettaïeb A, Jaffrézou JP.

FASEB J. 1998 Jan;12(1):101-9.

PMID:
9438415
36.

Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis.

Jaffrézou JP, Levade T, Bettaïeb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G.

EMBO J. 1996 May 15;15(10):2417-24.

Supplemental Content

Loading ...
Support Center